Evidence map›Paper›PMID 42239613›Full record

ArticleThe Journal of clinical and aesthetic dermatology

Challenges of Treating Recurrent Merkel Cell Carcinoma in the Rural US: A Case Report.

Chantel K Hillestad

Abstract readCase Reports
In one paragraph

Article in The Journal of clinical and aesthetic dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Chantel K HillestadMs. Hillestad is with Trinity Health, Minot, North Dakota.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 80-year-old White male individual presented with a rapidly growing lesion on his left forearm that had been increasing in size for the past 2 months. The patient resides in a northern rural state with limited access to dermatology care. The shave biopsy performed indicated Merkel cell carcinoma (MCC). The patient was referred to oncology and surgical oncology. The patient underwent a wide local excision, then adjuvant immunotherapy with pembrolizumab. The patient presented 2 years later with a rapidly growing lesion on the left forearm in the location of the prior surgical scar, and this was found to be recurrent MCC. Two months later, a new lesion developed approximately 7 cm from the most recent surgical incision; this was also found to be MCC. MCC is a rare form of skin cancer that is the most fatal, is more invasive than other types of skin cancer, and has a high rate of mortality. Diagnosis is confirmed by biopsy. Currently, no screening tests are in place regarding MCC or recurrent MCC. Treatment often involves wide local surgical excision and radiation therapy. Adjuvant immunotherapy and targeted therapies are promising treatment options and are continuing to evolve. Patients diagnosed with MCC in rural areas have been found to have decreased life expectancy compared to urban patients. Rural patients often encounter extraneous challenges involving travel, limited access to care, and financial hardship compared to urban patients. Treating rural patients can pose challenges to the clinician involving access to care barriers, nonadherence, patient inducement, and adhering to clinical guidelines to achieve the best outcome.

Indexed as

adjuvant chemotherapyadjuvant immunotherapyadjuvant radiation therapyMerkel cell carcinomaMerkel cell polyomaviruspositron emission tomography (PET) scanreceptor tyrosine kinase inhibitorssentinel lymph node biopsy

Identifiers

PMID42239613
PMCPMC13229156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.